NDA Submitted for HIV Treatment

Drug Industry Daily
KEYWORDS Drug Approvals / FDA
A A

Bristol-Myers Squibb and Gilead Sciences have submitted a new drug application (NDA) to the FDA for a product that combines two anti-HIV medications in a once-a-day single tablet regimen.

To View This Article:

Login

Subscribe To Drug Industry Daily